These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 25721150)

  • 41. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
    Johansson AK; Juhlin T; Engdahl J; Lind S; Hagwall K; Rorsman C; Fodor E; Alenholt A; Paul Nordin A; Rosenqvist M; Frick M
    Europace; 2015 Oct; 17(10):1514-7. PubMed ID: 26017466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
    Crivera C; Nelson WW; Bookhart B; Martin S; Germain G; Laliberté F; Schein J; Lefebvre P
    Curr Med Res Opin; 2015; 31(10):1889-95. PubMed ID: 26211815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
    Lasek-Bal A; Urbanek T; Gierek D
    Int Angiol; 2015 Dec; 34(6):552-61. PubMed ID: 25410296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
    Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC;
    Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
    Koektuerk B; Turan CH; Yorgun H; Keskin K; Schoett M; Dahmen A; Gorr E; Yang A; Hoppe C; Horlitz M; Turan RG
    Cardiovasc Ther; 2016 Jun; 34(3):144-51. PubMed ID: 26880220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
    Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre.
    Sharif Z; Srinivas B; Tiedt I; Ryan N; Awadalla M; Sullivan V; Foley DP; Gumbrielle T; McAdam B; Sheahan RG
    Ir J Med Sci; 2017 Aug; 186(3):615-620. PubMed ID: 28233168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
    Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
    Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
    Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
    Nakase T; Moroi J; Ishikawa T
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1174-1177. PubMed ID: 29276013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
    Pratt NL; Ramsay E; Kalisch Ellett LM; Duszynski K; Shakib S; Kerr M; Caughey G; Roughead EE
    BMJ Open; 2019 May; 9(5):e026486. PubMed ID: 31061039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections.
    Caprio FZ; Bernstein RA; Alberts MJ; Curran Y; Bergman D; Korutz AW; Syed F; Ansari SA; Prabhakaran S
    Cerebrovasc Dis; 2014; 38(4):247-53. PubMed ID: 25401389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
    Tittl L; Endig S; Marten S; Reitter A; Beyer-Westendorf I; Beyer-Westendorf J
    Int J Cardiol; 2018 Jul; 262():85-91. PubMed ID: 29622509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack.
    Patel PA; Zhao X; Fonarow GC; Lytle BL; Smith EE; Xian Y; Bhatt DL; Peterson ED; Schwamm LH; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2015 Jul; 8(4):383-92. PubMed ID: 26058721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
    Pol D; Curtis C; Ramkumar S; Bittinger L
    Heart Lung Circ; 2019 Apr; 28(4):e40-e42. PubMed ID: 29861320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin.
    Zhao Y; Yang Y; Tang X; Yu X; Zhang L; Xiao H
    J Interv Card Electrophysiol; 2017 Apr; 48(3):267-282. PubMed ID: 28078536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
    Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
    BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.